Structural and Molecular Neuroplasticity in Migraine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03004313 |
Recruitment Status :
Completed
First Posted : December 28, 2016
Last Update Posted : November 24, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Migraine | Procedure: Pet Scan Procedure: MRI scan Procedure: Quantitative Sensory Testing (QST) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 32 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Structural and Molecular Neuroplasticity in Migraine |
Study Start Date : | January 2011 |
Actual Primary Completion Date : | October 2014 |
Actual Study Completion Date : | October 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Migraine
20 subjects experiencing 1-14 migraines per month will undergo the following:
|
Procedure: Pet Scan
Subjects will undergo Pet Scanning for 90 minutes Procedure: MRI scan Procedure: Quantitative Sensory Testing (QST) |
Active Comparator: Healthy
20 healthy subjects will undergo the following:
|
Procedure: Pet Scan
Subjects will undergo Pet Scanning for 90 minutes Procedure: MRI scan Procedure: Quantitative Sensory Testing (QST) |
- Level of mu-opioid receptor binding potential in the brain of episodic migraineurs during and outside the headache attack and compared to healthy controls. [ Time Frame: 90 min PET scan ]
- Correlation of migraine attack severity in migraineurs with mu-opioid receptor binding potential [ Time Frame: 90 min PET scan ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Between 18-45 years of age
- Between 1-14 migraine attacks per month or healthy
Exclusion Criteria:
- Cannot be taking daily migraine medication
- Healthy subjects cannot be taking hormonal birth control pills or other medication
- Cannot have chronic pain or a neurologic/psychiatric disorder such as: multiple sclerosis and bipolar disorder.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03004313
United States, Michigan | |
University of Michigan - Michigan Center for Oral Health Research | |
Ann Arbor, Michigan, United States, 48106 |
Principal Investigator: | Alexandre DaSilva, DDS, MS | University of Michigan |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Alexandre DaSilva, DDS, MS, Principal Investigator, Director of Headache and Orofacial Pain Effort, University of Michigan |
ClinicalTrials.gov Identifier: | NCT03004313 History of Changes |
Other Study ID Numbers: |
HUM00027383 |
First Posted: | December 28, 2016 Key Record Dates |
Last Update Posted: | November 24, 2017 |
Last Verified: | November 2017 |
migraine |
Migraine Disorders Headache Disorders, Primary Headache Disorders |
Brain Diseases Central Nervous System Diseases Nervous System Diseases |